Harbin Pharmaceutical Group Co

Harbin Pharmaceutical Group Co Inventory

The Inventory of Harbin Pharmaceutical Group Co (600664.SS) as of Oct 21, 2026 is 2.06 B CNY. In the previous year, Inventory was 1.89 B CNY — a change of 8.98% (higher).

Inventory

2.06 BCNY

YoY

8.98%

Last updated:

Inventory of Harbin Pharmaceutical Group Co is 2025 2.06 B CNY. Inventory of Harbin Pharmaceutical Group Co was 2024 1.89 B CNY. It decreases by 8.98% higher compared to the previous year.

The Harbin Pharmaceutical Group Co Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2018
1.69 B CNY
Jan 1, 2019
2.03 B CNY
Jan 1, 2020
1.86 B CNY
Jan 1, 2021
2.06 B CNY
Jan 1, 2022
1.80 B CNY
Jan 1, 2023
1.92 B CNY
Jan 1, 2024
1.89 B CNY
Jan 1, 2025
2.06 B CNY
The Harbin Pharmaceutical Group Co Inventory history
YEARInventoryYoY
2.06 BCNY+8.98%
1.89 BCNY-1.72%
1.92 BCNY+6.66%
1.80 BCNY-12.58%
2.06 BCNY+10.85%
1.86 BCNY-8.11%
2.03 BCNY+20.23%
1.69 BCNY-2.64%
1.73 BCNY-1.02%
1.75 BCNY-21.46%
2.23 BCNY-33.39%
3.34 BCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Harbin Pharmaceutical Group Co Stock analysis

What does Harbin Pharmaceutical Group Co do? Harbin Pharmaceutical Group Co., Ltd. generates revenue by engaging in the research, development, manufacture, wholesale, and retail of pharmaceutical products. The firm focuses on innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals. These activities support its main business sectors, which include antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The company produces a wide range of items, including calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, and Xingaizhonggai high calcium tablets. The business is structured around these diverse product lines, serving the needs of the pharmaceutical commerce sector and consumers requiring specific medical treatments. By covering the entire value chain from research and development to retail, the company monetizes its expertise in high-tech fields. The products listed, such as Shuanghuanglian oral solution and amoxicillin capsules, represent the tangible outputs of its manufacturing and wholesale operations, which are central to its financial model. Harbin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Harbin Pharmaceutical Group Co stock

Inventory of Harbin Pharmaceutical Group Co is 2.06 B CNY in 2025.

Inventory of Harbin Pharmaceutical Group Co changed from 1.89 B CNY to 2.06 B CNY, representing a 8.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory Harbin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Harbin Pharmaceutical Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Harbin Pharmaceutical Group Co

All Key Metrics — Harbin Pharmaceutical Group Co